X
Details:
Company intends to use the net proceeds from the offering for the previously announced registration study for VAL-083 in newly diagnosed and recurrent glioblastoma multiforme, the 15-patient REM-001 confirmatory lead-in study and for working capital.
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: VAL-083
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $19.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 18, 2020
RDD 2024
Not Confirmed
Contact SupplierDetails:
This combination brings together DelMar's first-in-class, DNA-targeting chemotherapeutic with proven anti-cancer activities with Adgero's photodynamic therapy platform.
Lead Product(s): Dianhydrogalactitol
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Adgero Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 10, 2020
RDD 2024
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Minakem is manufacturing small molecules APIs including corticosteroids
